10-Q: Hoth Therapeutics Reports Q3 2024 Financial Results, Cites Progress in Clinical Programs

Hoth Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing research and development efforts and a decrease in net loss compared to the same period last year.

Summary

• Hoth Therapeutics reported a net loss of $2.1 million for both the three months ended September 30, 2024 and 2023, with a basic and diluted loss per share of $0.31 and $0.60 respectively.
• For the nine months ended September 30, 2024, the company's net loss was $5.8 million, or $0.96 per share, compared to a net loss of $6.1 million, or $1.99 per share, for the same period in 2023.
• Research and development expenses decreased to $1.9 million for the nine months ended September 30, 2024, from $2.6 million in the same period of 2023.
• General and administrative expenses increased to $3.9 million for the nine months ended September 30, 2024, from $3.4 million in the same period of 2023.
• The company's cash and cash equivalents totaled $8.0 million as of September 30, 2024, with a working capital of approximately $7.4 million.
• Hoth Therapeutics believes its current cash is sufficient to fund operations for at least the next 12 months.
• The company will need to raise additional funding to develop and seek regulatory approvals for its product candidates.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still incurring losses, there is a decrease in net loss and a reduction in R&D expenses, which are positive signs. However, the need for additional funding and the risk of Nasdaq delisting temper the overall sentiment.

Positives

• The company experienced a decrease in net loss for the nine months ended September 30, 2024, compared to the same period in 2023.
• Research and development expenses decreased by 24.8% for the nine months ended September 30, 2024, compared to the same period in 2023.
• The company successfully raised approximately $3.8 million through the exercise of warrants.
• Hoth Therapeutics believes its current cash is sufficient to fund operations for at least the next 12 months.

Negatives

• The company continues to incur significant operating losses.
• Hoth Therapeutics has an accumulated deficit of approximately $58.7 million.
• The company will need to raise additional funding to develop and seek regulatory approvals for its product candidates.
• General and administrative expenses increased by 13.8% for the nine months ended September 30, 2024, compared to the same period in 2023.

Risks

• The company's ability to raise sufficient funds through the sale of debt or equity securities is subject to many risks and uncertainties.
• Future equity issuances may result in dilution to existing shareholders.
• Future debt securities may contain covenants that limit the company's operations.
• If additional funding is not available, the company's current development plan may be curtailed.
• The company is subject to the risk of not being able to maintain its Nasdaq listing due to the minimum bid price requirement.

Future Outlook

The company expects its research and development activities and general and administrative expenses to increase as it develops its existing product candidates and potentially acquires new product candidates. The company will need to raise additional funding to develop and seek regulatory approvals for its product candidates.

Management Comments

• Management believes its current cash is sufficient to fund operations for at least the next 12 months.
• Management acknowledges the need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements.

Industry Context

Hoth Therapeutics is operating in the competitive biopharmaceutical industry, where companies are focused on developing new therapies for unmet medical needs. The company's focus on various therapeutic areas, including cancer side effects, mast-cell derived cancers, traumatic brain injury, and Alzheimer's, aligns with current industry trends in addressing significant health challenges. The company's reliance on third-party organizations for clinical trials and research is a common practice in the industry.

Comparison to Industry Standards

• Hoth Therapeutics' financial results are typical for a clinical-stage biopharmaceutical company that is still in the development phase and not yet generating revenue from product sales.
• The company's research and development expenses are in line with industry standards for companies developing multiple drug candidates.
• The company's reliance on external funding through equity and debt offerings is a common practice for companies in this sector.
• Compared to companies like Cassava Sciences (SAVA) and Anavex Life Sciences (AVXL), which are also focused on neurodegenerative diseases, Hoth's cash position is relatively modest, highlighting the need for further capital raises.
• Similar to companies like Amylyx Pharmaceuticals (AMLX) and Biohaven Pharmaceutical (BHVN), Hoth is navigating the challenges of clinical trials and regulatory approvals, which are costly and time-consuming.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Employees may be affected by potential changes in the company's development plans.
• Customers and patients may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to develop its existing product candidates.
• The company may acquire new product candidates.
• The company will seek regulatory approvals for its product candidates.
• The company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements.
• The company will need to regain compliance with the Nasdaq minimum bid price requirement by April 28, 2025.

Key Dates

Keywords

biopharmaceutical, clinical-stage, research and development, net loss, financial results, HT-001, HT-KIT, HT-TBI, HT-ALZ, atopic dermatitis, asthma, allergies, acne, inflammatory bowel diseases, lupus, COVID-19